tradingkey.logo

Procept Biorobotics Corp

PRCT
查看详细走势图
28.740USD
+1.340+4.89%
收盘 02/06, 16:00美东报价延迟15分钟
1.61B总市值
亏损市盈率 TTM

Procept Biorobotics Corp

28.740
+1.340+4.89%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

+4.89%

5天

-0.76%

1月

-15.27%

6月

-27.41%

今年开始到现在

-8.65%

1年

-58.68%

查看详细走势图

TradingKey Procept Biorobotics Corp股票评分

单位: USD 更新时间: 2026-02-06

操作建议

Procept Biorobotics Corp当前公司基本面数据相对非常健康,最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理,在医疗设备与耗材行业排名34/205位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价52.75。中期看,股价处于平稳状态。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Procept Biorobotics Corp评分

相关信息

行业排名
34 / 205
全市场排名
122 / 4521
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

公司舆情

过去24小时
热度

过冷
过热
看好

Procept Biorobotics Corp亮点

亮点风险
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
业绩高增长
公司营业收入稳步增长,连续3年增长199.27%
估值高估
公司最新PE估值-18.74,处于3年历史高位
机构减仓
最新机构持股59.67M股,环比减少3.70%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓,最新持仓市值1.34K
活跃度增加
近期活跃度增加,过去20天平均换手率0.66

分析师目标

根据 14 位分析师
买入
评级
52.750
目标均价
+82.34%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Procept Biorobotics Corp新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Procept Biorobotics Corp简介

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
公司代码PRCT
公司Procept Biorobotics Corp
CEOWood (Larry L)
网址https://www.procept-biorobotics.com/
KeyAI